Allogeneic hemopoietic stem cell transplantation (HSCT) is the only curative option for many patients with hematological malignancies. Since many of these patients lack HLA-identical sibling donors and are older or have comorbidity, a fully ablative HSCT is not feasible and an alternative approach is required. We studied 22 consecutive patients who could not have myeloablative conditioning because of comorbidity or age -21/22 being over the age of 50 years (median 58 years range 20-70 years). A conditioning regimen consisting of fludarabine, total body radiation 450 cGy and alemtuzumab (CD52 mAb) was used for 15 patients. A second group of seven patients received CD45 monoclonal antibodies in addition. Unrelated donor stem cells were HLA matched (15 patients -68%) or one locus mismatched (seven patients -32%). In all, 16 patients had high-risk disease, including 12 with active malignancy at the time of transplant. With a median follow-up of 715 (216-1470) days, nonrelapse mortality, actuarial event-free and overall survival is 27, 45 and 45%, respectively. Hence the outcome of reduced intensity HSCT with lymphodepleting antibodies in older patients with intermediate/ high-risk hematological malignancies appears comparable to that obtained with fully ablative transplantation in younger patients, even when these older recipients lack HLA-identical sibling donors.
Summary:
Allogeneic hemopoietic stem cell transplantation (HSCT) is the only curative option for many patients with hematological malignancies. Since many of these patients lack HLA-identical sibling donors and are older or have comorbidity, a fully ablative HSCT is not feasible and an alternative approach is required. We studied 22 consecutive patients who could not have myeloablative conditioning because of comorbidity or age -21/22 being over the age of 50 years (median 58 years range 20-70 years). A conditioning regimen consisting of fludarabine, total body radiation 450 cGy and alemtuzumab (CD52 mAb) was used for 15 patients. A second group of seven patients received CD45 monoclonal antibodies in addition. Unrelated donor stem cells were HLA matched (15 patients -68%) or one locus mismatched (seven patients -32%). In all, 16 patients had high-risk disease, including 12 with active malignancy at the time of transplant. With a median follow-up of 715 (216-1470) days, nonrelapse mortality, actuarial event-free and overall survival is 27, 45 and 45%, respectively. Hence the outcome of reduced intensity HSCT with lymphodepleting antibodies in older patients with intermediate/ high-risk hematological malignancies appears comparable to that obtained with fully ablative transplantation in younger patients, even when these older recipients lack HLA-identical sibling donors. Many patients with hematologic malignancies are unsuited to conventional hemopoietic stem cell transplantation (HSCT), either because of advanced age, comorbidity or lack of an MHC-identical family donor. Introduction of reduced intensity conditioning regimens (RIC) has helped broaden the applicability of the procedure, [1] [2] [3] [4] [5] [6] [7] but older patients lacking an MHC-identical sibling are still generally considered inappropriate for HSCT because of the higher probability of graft rejection and graft-versus-host disease (GVHD), and a high treatment-related mortality. 8 One way to reduce these risks may be to use lympholytic monoclonal antibodies, depleting both the host immune system (to enhance engraftment) and the engrafted donor T cells (to reduce GVHD). Alemtuzumab, a humanized monoclonal antibody targeting CD52 antigen present on lymphocytes and monocytes may fit this requirement. Given pretransplant, it depletes recipient lymphocytes, thus enhancing engraftment, and because of its long half-life, it remains in circulation for several weeks post-stem cell infusion, thereby depleting donor T cells and reducing GVHD. [9] [10] [11] Monoclonal antibodies targeting the common leucocyte antigen CD45, 12 an antigen present on hematopoietic precursors and all leucocytes, may complement CD52 mAb, since they enhanced engraftment in an MHC mismatched murine stem cell transplant model. 13 They were also well tolerated and lymphodepleting in a phase I study in patients with advanced hematological malignancies. 14 We therefore devised two reduced intensity conditioning regimens, both incorporating low-dose radiation and Fludarabine. The first used alemtuzumab alone, while the second added CD45 mAb. We assessed the safety and outcome of this regimen in patients with intermediate-or high-risk hematological malignancies who were ineligible for myeloablative transplant because of age or comorbidity, and who lacked an MHC-matched sibling donor.
Patients and methods

Eligibility criteria
Patients with high/intermediate-risk hematological malignancies, who were ineligible for a myeloablative transplant because of older age or a comorbid illness, were entered on study if they had HLA A, B and DRB1 matching (6/6) or a one antigen mismatched (5/6) unrelated donor. The mismatch was permitted at any of the three loci. HLA A and B antigens were typed by intermediate resolution DNA typing with equivalent sensitivity to serologic typing, and DRB1 was typed by high-resolution DNA typing. Patients were excluded if they were HIV positive or pregnant, had unstable angina or decompensated congestive heart failure (with ECOG performance status of 3 or 4), severe pulmonary disease requiring oxygen (with ECOG performance status of 3 or 4), stroke in the previous 6 months or Child's class C cirrhosis.
Of the 22 patients who fulfilled the above criteria and were registered on the study, all but one were older than 50 years. None were eligible for myeloablative transplantation because of age and/or comorbidities ( Table 1 ). Patients were treated at a single institution on two consecutive protocols, both of which were approved by the Institutional Review Board and performed under an investigator sponsored IND application to the FDA. All patients signed an informed consent and outcomes were provided to our Data Safety Monitoring Committee.
Patient characteristics
Detailed characteristics of 22 consecutive patients enrolled in the study are shown in Table 2 . There were 17 males and five females with a median age of 58 years (range 20-70 years). Diagnoses were acute myeloid leukemia (AML) (n ¼ 6), AML secondary to myelodysplastic syndrome (MDS) (n ¼ 4), acute lymphoblastic leukemia (ALL) (n ¼ 3), MDS-refractory anemia (n ¼ 1), myelofibrosis (MF) (n ¼ 1), accelerated phase chronic myeloid leukemia (CML) (n ¼ 1), primary refractory non-Hodgkin lymphoma (NHL) (n ¼ 4), and refractory chronic lymphocytic leukemia (n ¼ 2). Most patients had high-risk disease with 12 patients having active disease and four being in second remission. Six patients were in first complete remission of poor prognosis leukemia indicated by complex cytogenetics (n ¼ 2), monosomy seven (n ¼ 1), AML with underlying MDS (n ¼ 1), and Ph þ ALL (n ¼ 2). Patients received stem cells from a 6/6 antigen matched unrelated donor (n ¼ 15), or a one antigen mismatched unrelated donor (n ¼ 7). Five donors were mismatched at the HLA DRB1 locus, one was mismatched at the HLA A locus and one at the HLA B locus. In all, 20 patients, or their donors, or both were cytomegalovirus (CMV) seropositive, and were therefore at risk of CMV reactivation. For eight patients, the stem cell source was bone marrow; for the remaining 14 patients, mobilized peripheral blood stem cells were used. The median number of CD34 þ cells infused was 6.08 Â 10 6 /kg (range 0.05-17.0 Â 10 6 /kg).
Conditioning regimen
In protocol 1, patients received total body radiation 450 cGy (day À6), fludarabine 30 mg/m 2 daily (days À5 to À2) and alemtuzumab 10 mg/daily (days À5 to À2). In protocol 2, patients received total body radiation 450 cGy (day À1) fludarabine 30 mg/m 2 daily (days À8 to À5), alemtuzumab 10 mg daily (days À8 to À6) and CD45 monoclonal antibodies (manufactured in the GMP facility at our institution and by the Therapeutic antibody center at Oxford) 0.4 mg/kg daily (days À5 to À2). Total body radiation was given in a single fraction at a dose rate of no more than 12 cGy/min. Tacrolimus was started at 0.03 mg/ kg/day IV by continuous infusion to maintain levels of 5-15 ng/ml in both sets of protocols to prevent GVHD. Patients were nursed in HEPA filtered rooms and were given standard supportive care. Antimicrobial prophylaxis was levofloxacin, fluconazole, acyclovir, ganciclovir after engraftment (for patients at risk of CMV reactivation), immunoglobulins, and cotrimoxazole.
Chimerism analysis
DNA was extracted, from mononuclear cells and granulocytes isolated from peripheral blood and bone marrow specimens. White blood cells were separated by Fico/Lite LymphoH density gradient separation (density: 1.07770.001 g/l, osmolality: 290710 m Osm, Atlanta Biological, Lawrenceville, CA, USA). DNA extracted from these tissues and blood samples was amplified with 10 short tandem repeat (STR) primer pairs obtained from the AmpFeSTR Profiler Plus PCR Amplification Kit (Applied Biosystems, Foster City, CA, USA). The fluorescentlabeled PCR products were separated by gel electrophoresis on an Applied Biosystems 377 DNA Sequencer (Applied Biosystems, Foster City, CA, USA). Donor chimerism was determined by quantization of the size differences of anmplified PCR products. The GeneScan software (Applied Biosystems) was used to correlate allele peak areas to the percentage of donor and recipient DNA. The sensitivity level of this procedure averages 5.6% for the 10 markers used.
Study end points
The major study end point was sustained allogeneic engraftment. Secondary outcomes included the incidence and severity of GVHD, nonrelapse mortality, event-free and overall survival. Neutrophil recovery was defined as the first of three consecutive days with a neutrophil count of more than 0.5 Â 10 9 /l. Platelet recovery was defined as the first of three consecutive days with a platelet count of more than 20 Â 10 9 /l without support. Graft rejection was defined as absence of any donor cells on chimerism studies. GVHD, disease response and progression were defined by standard criteria. Event-free survival was calculated from the date of transplant to the date of relapse, progression, or death.
Statistical analysis
Data were summarized using descriptive statistics. Differences in proportions were analyzed using Fisher's twotailed exact test. Cumulative incidences were calculated for GVHD and CMV reactivation; death and graft rejection were treated as competing events. Overall and event-free survival were calculated using Kaplan-Meier method (see Figure 1 ).
Results (Table 3)
Engraftment
Neutrophil recovery (absolute neutrophil count greater than 0.5 Â 10 9 /l) occurred in 21/22 (95%) patients at a median time of 12 days (range 4-25 days), while platelet recovery (count greater than 20 Â 10 9 /l) happened at 19 days (range 14-205 days). One patient died of resistant pseudomonas sepsis on day 8 and was not evaluable for engraftment, while one patient failed to engraft on protocol 1 but subsequently engrafted on protocol 2 (which adds anti-CD45 monoclonal antibodies). Two additional patients rejected their grafts after initial neutrophil recovery, on days 64 and 124. All three patients with primary or secondary graft failure had received a transplant from a one antigen mismatched (five of six antigen matching) unrelated donor. a All 3 (out of seven) had one antigen (5/6) mismatched donor, and 1 of these three patients subsequently engrafted when anti-CD45 monoclonal antibody was used.
Chimerism study
Chimerism studies at day 30 showed that 15 patients had 100% donor peripheral blood mononuclear cells and granulocytes, one patient had recipient cells only, and six patients had mixed chimerism with both donor and recipient cells. Of these latter six patients, two were the patients described above who rejected the graft at 64 and 124 days, respectively, post transplant, and two had disease relapse, while the remaining two subsequently developed full donor chimerism (one after withdrawal of FK506 immunosuppression and the other after donor lymphocyte infusion). The source of stem cells influenced the probability of developing full donor chimerism at day 30, since this status was attained by only 2/7 patients receiving bone marrow stem cells compared to 13 /15 patients who received peripheral blood stem cells (P ¼ 0.01 Fisher's exact test-two tailed). Other factors including the conditioning regimen (with or without CD45) or donor match (fully matched or one HLA antigen mismatched) did not influence the probability of attaining full chimerism.
Graft-versus-host disease
The cumulative incidence of acute grade II-IV GVHD was 32% (n ¼ 7), but only one patient had severe grade III-IV GVHD with a cumulative incidence of 5%. Five out of 12 evaluable patients had chronic GVHD (cumulative incidence 23%), which was limited in three patients and extensive in the remaining two.
Relapse
Six patients had clinical and morphological relapse of their original malignancy, which was fatal. Two additional patients had molecular relapse. One was diagnosed by FISH analysis for monosomy 7 in a patient with AML and responded to rapid tacrolimus taper. The second was detected by PCR amplification of bcr/abl in a patient with ALL and responded to donor lymphocyte infusion and imatinib. Both patients remain in remission.
Toxicity and survival
After a median follow-up of 716 days (range 216-1470 days), actuarial event-free and overall survival is 45%( 95% CI; 24-66%) and 48%(95% CI; 24-66%), respectively. In all, 10 of 22 patients are currently alive and are in remission; six patients died due to recurrent disease, and the causes of death in the remaining six patients were as follows: bacterial sepsis (Staphalveouas aureus 1, Pseudomonas 1), viral infection (adenovirus, one), disseminated toxoplasmosis (one), GVHD (one) and graft failure and Guillian Barre syndrome (one). Monoclonal antibodies were well tolerated without any severe grade 3-5 nonhematological toxicity. The main infusion-related adverse events were mild (grade 1 or 2) fever and erythematous or urticarial skin reaction occurring in 55 and 59% of patients, respectively. CMV antigenemia was seen at a median of 24 days post transplant (range 5-138 days) in 13 patients, with a cumulative incidence of 59% (95% CI; 42-84%); however, only one patient developed CMV disease -CMV colitis that was successfully treated with ganciclovir. None of the patients developed an EBV lymphoproliferative disorder.
Discussion
We have shown that subablative transplantation with unrelated donor stem cells is a feasible treatment option for a population who for reasons of age, comorbidity or lack of an HLA-identical sibling are unsuited to conventional stem cell transplantation. Of 22 evaluable patients with a median age of 58 years, three (14%) had primary or secondary graft rejection, and only one patient developed grade III-IV aGVHD. Five patients developed cGVHD, which was extensive in two. Although 16 patients had highrisk disease at study entry (in 12 of whom the malignancy was active), 45% are disease-free and overall survivors; seven of 10 surviving patients had high-risk disease.
Since our study was targeted to patients who lacked MHC-identical siblings, we reasoned that the greatest risk of treatment-related morbidity and mortality would come from graft rejection and GVHD. 8, 15, 16 Accordingly, we developed two sequential protocols to assess the safety of adding lymphodepleting mAb. The first contained alemtuzumab (CD52) as a supplementary immunosuppressive mAb, while the second combined alemtuzumab and CD45 mAb. Administration of alemtuzumab pre-transplant can supplement conventional small molecule preparative drugs in reduced intensity and conventional HSCT. It depletes immune cells in the host and in the donor graft, reducing rejection and GVHD, respectively. This first protocol indicated consistent engraftment in patients receiving HLA fully matched donors with 10/10 engrafting (measured by neutrophil and (platelet recovery) and 7/10 obtaining full donor chimerism at day 30. By contrast, only 2/4 patients receiving an HLA mismatched HSCT showed sustained engraftment. As part of our planned progression towards increasing the mAb-mediated immunosuppression of the recipient to reduce rejection, our second protocol incorporated CD45 as a short acting lymphocyte depleting antibody. We have previously shown that this mAb has a half-life of circa 8 h, in part because newly emerging hemopoietic cells from the marrow express increasing levels of the CD45 antigen and act as a 'sink' for residual MAb.
14 Moreover, as a rat IgG2b mAb, the half-life in human serum would be expected to be considerably lower than the 10-28 days recorded for the 'humanized' alemtuzumab. This short half-life means that the antibody will contribute to recipient T-cell depletion but, unlike alemtuzumab, will be absent when donor stem cells are infused. This split activity may favor engraftment of the donor population. Addition of CD45 in protocol 2 was well tolerated. Although the study was not powered to discover whether or not the agent would effectively add to the benefit of alemtuzumab by further reducing the rate of rejection, none of the recipients of an HLA matched unrelated graft rejected, and 3/4 recipients of one antigen mismatched stem cell transplant engrafted, including one of the patients who had rejected a mismatched graft on protocol 1, in which alemtuzumab was the sole immunosuppressive mAb.
Overall, none of the recipients of HLA matched unrelated stem cell transplants had graft rejection, an incidence which compares favorably with that reported in previous studies of RIC regimens (0-21%). It will be of interest to see if addition of CD45 mAbs will consistently reduce the rejection risk in a larger series of one antigen mismatched donors.
Our data also show that administration of peripheral blood stem cells (PBSC) as opposed to bone marrow stem cells is significantly (P ¼ 0.01) more likely to produce 100% donor hematopoiesis at day 30, Although unrelated donors obviously cannot be compelled to provide PBSC rather than marrow, these results suggest that when a choice between these stem cell sources is possible, then donation of PBSC is to be preferred, particularly when donor and recipient are HLA mismatched.
The incidence of severe/fatal GVHD (5%) in this series was low, although 27% of patients had grade II disease. This risk of severe/fatal GVHD is less than the 10-20% observed without alemtuzumab [17] [18] [19] [20] [21] (Table 4) , and substantially lower than the 31-47% rate reported after conventional conditioning even in younger patients. 18, [22] [23] [24] The low incidence likely reflects the ability of alemtuzumab to remain in the circulation for several weeks after infusion of cells. 25 Overall, we observed a transplant-related mortality of 27% compared to 19-55% seen with other reduced intensity conditioning regimens in matched unrelated donors [17] [18] [19] [20] [21] 26 and the 32-61% rate observed after the myeloablative conditioning of younger patients. 18, 22, 24, 27 In summary, hematopoietic stem cell transplantation using reduced intensity conditioning with lympholytic antibodies and alternative donor stem cells is a feasible option even for patients over the age of 50 years who have intermediate-or high-risk disease, offering the potential of cure for otherwise intractable hematopoietic neoplasms. 
